Secondary analysis of SOUL (9,650 patients with type 2 diabetes and ASCVD and/or CKD): oral semaglutide vs placebo did not significantly reduce the five-point kidney composite (8.4% vs 9.0%; HR 0.91) but slowed annual eGFR decline.
Secondary analysisn = 9,650
Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial